ULTRAGENYX
NASDAQ: RARE (Ultragenyx Pharmaceutical Inc.)
Last update: 23 hours ago23.94
0.68 (2.92%)
| Previous Close | 23.26 |
| Open | 23.52 |
| Volume | 1,783,574 |
| Avg. Volume (3M) | 1,872,866 |
| Market Cap | 2,357,832,192 |
| Price / Sales | 3.46 |
| Price / Book | 247.70 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Profit Margin | -93.04% |
| Operating Margin (TTM) | -102.62% |
| Diluted EPS (TTM) | -5.83 |
| Quarterly Revenue Growth (YOY) | 28.00% |
| Total Debt/Equity (MRQ) | 588.24% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -389.94 M |
| Levered Free Cash Flow (TTM) | -172.94 M |
| Return on Assets (TTM) | -24.51% |
| Return on Equity (TTM) | -377.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.60 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.20% |
| % Held by Institutions | 99.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sands Capital Management, Llc | 31 Mar 2026 | 3,214,533 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SULIMAN SHEHNAAZ | - | 24.19 | -5,740 | -138,851 |
| Aggregate Net Quantity | -5,740 | |||
| Aggregate Net Value ($) | -138,851 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 24.19 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SULIMAN SHEHNAAZ | Director | 18 May 2026 | Sell (-) | 5,740 | 24.19 | 138,851 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |